Etanercept
- Generic Name
- Etanercept
- Brand Names
- Enbrel, Eticovo, Benepali, Erelzi, Nepexto
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 185243-69-0
- Unique Ingredient Identifier
- OP401G7OJC
- Background
Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1. The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of IgG1. Etanercept is produced by recombinant DNA technolo...
- Indication
Etanercept is indicated for the treatment of moderately to severely active rheumatoid arthritis in adults and in chronic moderate to severe plaque psoriasis in patients 4 years of age and older. It is also used to manage signs and symptoms of polyarticular idiopathic arthritis and Juvenile Psoriatic Arthritis in those aged 2 years and older. Etanercept is al...
- Associated Conditions
- Active Juvenile Psoriatic Arthritis, Ankylosing Spondylitis (AS), Graft-versus-host Disease (GVHD), Polyarticular Juvenile Idiopathic Arthritis, Psoriasis Vulgaris (Plaque Psoriasis), Psoriatic Arthritis, Pyoderma Gangrenosum, Rheumatoid Arthritis, Severe Plaque psoriasis, Stevens-Johnson Syndrome, Chronic, severe Psoriatic Arthritis, Moderate Plaque psoriasis, Moderate, active Rheumatoid arthritis, Severe, active Rheumatoid arthritis
- Associated Therapies
- -
TNFalfa Blocking Treatment of Spondylarthropathies
- Conditions
- First Posted Date
- 2005-08-23
- Last Posted Date
- 2007-04-10
- Lead Sponsor
- Hvidovre University Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT00133315
- Locations
- 🇩🇰
Hvidovre University Hospital, Hvidovre, Denmark
🇩🇰Vejle Sygehus, Vejle, Denmark
🇩🇰Bispebjerg Hospital, Copenhagen, Denmark
REPArE: Rating Evaluations in Psoriatic Arthritis (PsA) With Etanercept (Enbrel®)
- First Posted Date
- 2005-08-09
- Last Posted Date
- 2014-04-24
- Lead Sponsor
- Amgen
- Target Recruit Count
- 110
- Registration Number
- NCT00127842
Study of Etanercept in the Treatment of Psoriasis in Adult Subjects
- Conditions
- First Posted Date
- 2005-07-21
- Last Posted Date
- 2009-03-06
- Lead Sponsor
- Amgen
- Target Recruit Count
- 391
- Registration Number
- NCT00121615
Organization of Teratology Information Services (OTIS) Autoimmune Diseases in Pregnancy Project
- First Posted Date
- 2005-06-29
- Last Posted Date
- 2023-10-06
- Lead Sponsor
- Amgen
- Target Recruit Count
- 830
- Registration Number
- NCT00116272
- Locations
- 🇺🇸
Research Site, San Diego, California, United States
Study to Help Understand the Action of the Drug Etanercept for the Adult Patient With Psoriasis
- First Posted Date
- 2005-06-28
- Last Posted Date
- 2011-03-18
- Lead Sponsor
- Rockefeller University
- Target Recruit Count
- 30
- Registration Number
- NCT00116181
- Locations
- 🇺🇸
Rockefeller University, New York, New York, United States
Evaluating Efficacy and Safety of Etanercept 50 mg Twice Weekly (BIW) in Rheumatoid Arthritis (RA) Subjects Who Are Sub-Optimal Responders to Etanercept 50 mg Once Weekly (QW)
- Conditions
- First Posted Date
- 2005-06-22
- Last Posted Date
- 2013-05-30
- Lead Sponsor
- Amgen
- Target Recruit Count
- 200
- Registration Number
- NCT00115219
A Pilot Study of Etanercept in Dermatomyositis
- First Posted Date
- 2005-06-03
- Last Posted Date
- 2011-06-21
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 16
- Registration Number
- NCT00112385
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Effects of Tumor Necrosis Factor (TNF)-Alpha Antagonism in Patients With Metabolic Syndrome
- First Posted Date
- 2005-05-27
- Last Posted Date
- 2017-10-06
- Target Recruit Count
- 56
- Registration Number
- NCT00111956
- Locations
- 🇺🇸
Mass General Hospital, Boston, Massachusetts, United States
Evaluating the Safety of Etanercept 50 mg Twice Weekly in Subjects With Psoriasis
- Conditions
- First Posted Date
- 2005-05-23
- Last Posted Date
- 2013-05-15
- Lead Sponsor
- Amgen
- Target Recruit Count
- 600
- Registration Number
- NCT00111449
Evaluating the Safety of Etanercept in the Treatment of Psoriasis in Adult Subjects
- First Posted Date
- 2005-05-23
- Last Posted Date
- 2013-04-26
- Lead Sponsor
- Amgen
- Target Recruit Count
- 912
- Registration Number
- NCT00111436
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.